• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
  • For Subscribers

Trendingnow

1

Sam Bankman-Fried’s former employer Jane Street poised for $35 billion windfall from purchase of Anthropic shares in FTX bankruptcy

2

‘Absurd’: Delta CEO says it takes longer to fly from ATL to LGA today than in the 1950s

3

The Trump White House is starting to admit that your bank account and airline tickets are under attack from rogue AI

1

Sam Bankman-Fried’s former employer Jane Street poised for $35 billion windfall from purchase of Anthropic shares in FTX bankruptcy

2

‘Absurd’: Delta CEO says it takes longer to fly from ATL to LGA today than in the 1950s

3

The Trump White House is starting to admit that your bank account and airline tickets are under attack from rogue AI
RetailFortune 500 Innovation Forum

Altria CEO says ‘responsibility needs to be at the heart’ of its FDA-regulated nicotine business. It’s part of why it sued the regulator

Sasha Rogelberg
By
Sasha Rogelberg
Sasha Rogelberg
Reporter
Down Arrow Button Icon
Sasha Rogelberg
By
Sasha Rogelberg
Sasha Rogelberg
Reporter
Down Arrow Button Icon
November 17, 2026, 2:37 PM ET
Sal Mancuso
Altria CEO Sal Mancuso said working with the FDA has presented challenges with the speed of regulatory approval and how the company competes on the market.Rebecca Greenfield—Fortune
Google source logo
Add Fortune on Google for similar content.

As Big Tobacco companies pivot away from combustible products to less harmful nicotine alternatives, they’re finding new challenges in their relationships with regulators.

Recommended Video

Sal Mancuso, the CEO of Altria Group, which owns cigarette and cigar brands like Marlboro and Black & Mild,  explained at the Fortune 500 Innovation Forum in Detroit on Monday that competing in a Food and Drug Administration-regulated industry brings with it both an added sense of responsibility to consumers, and hurdles in competing with other businesses in the space. Mancuso said that Altria’s On! nicotine pouch brand is a key innovation for the company, but regulations have slowed growth.

The Marlboro-maker announced its Moving Beyond Smoking initiative in 2023 as more consumers move away from cigarettes, putting a renewed focus on smoke-free alternatives to cigarettes such as NJOY vapes and On! nicotine pouches, which are competing with Philip Morris’s Zyn. 

“You can call us the underdog in the pouch category today, but our intention is to lead the pouch category over the long term,” Mancuso told Fortune Executive Editorial Director Diane Brady. “When you think about what’s maybe getting in the way, there’s a couple of factors: One is just the misperception that nicotine is what causes harm from tobacco use. Most of the harm is from combustion, so clarifying that misperception is important. And then we are regulated by the FDA. When you’re in the nicotine business, responsibility needs to be at the heart of everything you do.” 

Altria, through its subsidiaries Helix Innovations and NJOY, sued the FDA in September, claiming the agency blocked newer nicotine products from reaching the market through its review process, which the nicotine company is seeking to overhaul. Through the Premarket Tobacco Product Application (PMTA), the FDA is legally required to review new tobacco products before they reach market and decide if the product provides an overall public health benefit within 180 days of submitting an application. Altria claims the FDA has failed to meet that deadline, and that the regulator’s red tape and bureaucracy stalled newer On! products from reaching the market, while foreign competitors flood store shelves. 

The FDA said it would consider revisions to the PMTA and consider new rules as the market continues to change, and last month, U.S. District Judge James Wesley Hendrix of the Northern District of Texas granted a joint request from the FDA and the plaintiffs to pause litigation. 

Mancuso explained that Altria sued the FDA because it needed enforcement against illicit products. Reiterating what was in the lawsuit, he said what should take the FDA six months to review was taking six years in some cases, allowing illegal products, particularly from China, from not just taking market share, but also skirting standards Mancuso believes the FDA should keep in place to protect the safety of the consumer. He claimed competing overseas products are marketed in vape shops as made in the U.S.A, but are mislabeled.

“Quite frankly, the regulations are broken,” Mancuso said. “There’s too much information. We still want a high standard, but it should be streamlined. 

“Guidance is not durable,” he added. “It can be torn up immediately. What we want is more rapid authorization, so that consumers have product choices that they can choose from.” 

The regulatory landscape of nicotine is similar in some ways to how cannabis is being introduced and regulated in U.S. markets, Mancuso suggested, such that the substance is legal in half of U.S. states, but there’s no federal standard, creating a “hodgepodge” of regulations.

“Regulations are hard for any business,” Mancuso said. “At the very least, it should be an even playing field, not a playing field where bad actors are in a better position than responsible companies like ours.

Fortune Daily breaks the traditional barrier between audience and newsroom. The show transforms Fortune’s trusted reporting into actionable, conversational, and entertaining insights for an emerging class of business leaders. Watch here.
About the Author
Sasha Rogelberg
By Sasha RogelbergReporter
LinkedIn iconTwitter icon

Sasha Rogelberg is a reporter and former editorial fellow on the news desk at Fortune, covering retail and the intersection of business and popular culture.

See full bioRight Arrow Button Icon
Google source logo
Add Fortune on Google for similar content.

Latest in Retail


Most Popular

Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • TikTok icon
  • YouTube icon

    Recommended For You

    © 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
    FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.